Evidence map›Paper›PMID 35437631›Full record

ArticleTherapeutic innovation & regulatory science2022

Assessing the Risk of Decrease in Kidney Function in Patients Prescribed Direct-Acting Antivirals for Hepatitis C Utilizing the MID-NET

Tomoaki Hasegawa, Sono Sawada, Chieko Ishiguro, Takashi Ando, Kanae Kobayashi, Noriyuki Komiyama, Toyotaka Iguchi, Takahiro Nonaka, Yoshiaki Uyama

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic innovation & regulatory science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. New Function for Safety Signal Monitoring in MID-NETClinical and translational science · 2025
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Tomoaki HasegawaOffice of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo, 100-0013, Japan.ORCID 0000-0002-8602-8295
Sono SawadaOffice of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo, 100-0013, Japan.
Chieko IshiguroOffice of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo, 100-0013, Japan.ORCID 0000-0002-1302-9430
Takashi AndoOffice of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo, 100-0013, Japan.ORCID 0000-0002-0654-5656
Kanae KobayashiOffice of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Noriyuki KomiyamaOffice of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Toyotaka IguchiOffice of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Takahiro NonakaOffice of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo, 100-0013, Japan.ORCID 0000-0003-1320-6190
Yoshiaki UyamaOffice of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo, 100-0013, Japan. uyama-yoshiaki@pmda.go.jp.ORCID 0000-0002-0430-9887
Pharmaceuticals and Medical Devices Agency · JPNational Center for Global Health and Medicine · JPOsaka Metropolitan University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An association between kidney disease and direct-acting antivirals against hepatitis C (DAAs) has been suggested, however the warning on the package insert (PI) of the drug varies among DAAs. In this study, the risk of decreased kidney function associated with DAAs marketed in Japan was investigated to determine whether the risk of kidney disease is a common adverse event and class effect of DAAs. Data for patients who were new users of DAAs marketed in Japan, with eGFR ≥ 45 mL/min/1.73 m

Indexed as

Hepatitis CHepatitis C, ChronicAntiviral AgentsHepacivirusHumansJapanKidneyRibavirinAntiviral AgentsRibavirinDecreased kidney functionDirect-acting antivirals against hepatitis CDrug safetyPharmacoepidemiologyPharmacovigilanceReal world data

Identifiers

PMID35437631
PMCPMC9135840
OpenAlexW4224214129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.